01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
On 2 February 2021 the Federal Trade Commission (FTC) published the annual jurisdictional adjustment...
Read More >
M&A Monitor focuses on legal issues of interest to M&A practitioners for private and closely held co...
Read More >
The novel coronavirus outbreak was first alerted to the World Health Organisation (WHO) by Chinese a...
Read More >
What will the oil and gas landscape look like in 2021? Managing Director Gary Pittman discusses bank...
Read More >
I’m very outspoken, probably too much. Many people in the industry don’t like flamethrowers who ca...
Read More >
On December 8, 2020, in Taylor Morrison of Texas, Inc. v. Kohlmeyer, a Texas Court of Appeals reject...
Read More >